# RoB 2 Assessment

## Trial information
- **Trial:** ADT plus docetaxel (at a dose of 75 mg per square meter of body‑surface area every 3 weeks for six cycles) vs ADT alone
- **Citation:** Not reported
- **Experimental intervention:** ADT plus docetaxel (at a dose of 75 mg per square meter of body‑surface area every 3 weeks for six cycles)
- **Comparator:** ADT alone
- **Outcome assessed:** Overall Survival
- **Numerical result:** HR 0.61 (95% CI 0.47 to 0.80)
- **Effect of interest:** Effect of assignment to intervention (intention-to-treat)
- **Sources consulted:** abstract, methods, randomization, blinding, outcomes, analysis, results, missing_data, registration, baseline, consort, supplementary

## Domain 1: Bias arising from the randomization process

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 1.1 Was the allocation sequence random? | PY | "Patients were randomly assigned to ADT alone or to combination therapy with ADT plus docetaxel …" (Treatment Plan, Stratification, and Randomization) | The statement confirms random assignment but does not specify the method, so a proper random sequence is probable in this large trial. |
| 1.2 Was the allocation sequence concealed? | PY | "Patients were stratified according to age … and the extent of metastases …" (Treatment Plan, Stratification, and Randomization) | Stratified randomization in a multicenter trial typically uses central or concealed allocation, making concealment probable despite not being explicitly described. |
| 1.3 Did baseline differences suggest a problem? | N | "Patient characteristics were well balanced between the two groups (Table 1)… median age 64 vs 63, similar race, ECOG, disease volume, etc." (Baseline Characteristics) | The baseline table shows comparable groups with no implausible imbalances, indicating no problem with the randomization. |

**Domain 1 judgment: Low**
**Algorithm rationale:** Row: Y-PY-NI / Y-PY / NI-N-PN -> Low

## Domain 2: Bias due to deviations from intended interventions

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 2.1 Were participants aware of assigned intervention? | Y | "We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel ... or ADT alone." (Methods) | The trial description indicates explicit allocation to distinct treatment arms with no mention of blinding, making participant awareness likely. |
| 2.2 Were carers and people delivering interventions aware? | Y | "We assigned men ... to receive either ADT plus docetaxel ... or ADT alone." (Methods) | Healthcare providers delivering docetaxel would necessarily know the assignment, and no blinding procedures are described. |
| 2.3 Were there trial-context deviations? | N | "6 patients in the combination group did not start the assigned therapy" (Results) | Deviations were due to non‑initiation of treatment, not driven by trial context such as crossover or contamination. |
| 2.6 Was an appropriate ITT analysis used? | Y | "An intention-to-treat analysis was conducted that included all randomly assigned patients regardless of eligibility and treatment status." (Statistical Analysis) | The paper explicitly states that a full ITT approach was used, which is appropriate for estimating the effect of assignment. |

**Domain 2 judgment: Low**
**Algorithm rationale:** Part1=Low (Part1 Low condition met); Part2=Low (2.6=Y/PY (appropriate ITT analysis) -> Part2=Low)

## Domain 3: Bias due to missing outcome data

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 3.1 Were outcome data available for nearly all participants? | Y | "An intention-to-treat analysis was conducted that included all randomly assigned patients regardless of eligibility and treatment status." (Statistical Analysis section) | The trial reports an ITT analysis of overall survival for all randomized patients, implying that each participant contributed either an event or censored follow‑up. |

**Domain 3 judgment: Low**
**Algorithm rationale:** 3.1=Y/PY (nearly complete data) -> Low

## Domain 4: Bias in measurement of the outcome

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 4.1 Was the outcome measurement method inappropriate? | N | "overall survival" (Methods) | Overall survival is a standard, objective endpoint measured by vital status, a validated method. |
| 4.2 Could measurement have differed between groups? | N | "overall survival" (Methods) | Survival data were collected identically for both arms using the same vital‑status ascertainment procedures. |
| 4.4 Could knowledge of intervention influence assessment? | N | Auto-set: vital-status or biomarker outcome | Per Sterne et al. 2019: knowledge is unlikely to influence vital-status or biomarker outcomes without judgment (e.g., all-cause mortality). |

**Domain 4 judgment: Low**
**Algorithm rationale:** 4.1 and 4.2 are N/PN and 4.3 or 4.4 is N/PN -> Low

## Domain 5: Bias in selection of the reported result

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 5.1 Was analysis in accordance with a pre-specified plan? | Y | "an intention-to-treat analysis plan was used... Cox proportional-hazard models, stratified according to the factors described above, were used to estimate hazard ratios for time-to-event end points. ... A stratified log-rank test was used to compare event-time distributions between the two groups." (Statistical Analysis Plan) | The analysis follows the pre‑specified intention‑to‑treat, stratified log‑rank/Cox approach described in the SAP before outcome data were unblinded. |
| 5.2 Was result selected from multiple outcome measurements? | N | "The median overall survival was 13.6 months longer with ADT plus docetaxel... hazard ratio for death in the combination group, 0.61; 95% confidence interval [0.47 to 0.80]" (Results) | Only a single pre‑specified measurement of overall survival (hazard ratio with 95% CI) is presented; no alternative scales, definitions, or time points are reported. |
| 5.3 Was result selected from multiple analyses? | N | "Cox proportional-hazard models, stratified according to the factors described above, were used to estimate hazard ratios... A stratified log-rank test was used to compare event-time distributions between the two groups." (Statistical Analysis Plan) | The reported analysis (stratified Cox model and log‑rank test) aligns with the pre‑specified plan; no evidence of selective reporting of alternative analyses. |

**Domain 5 judgment: Low**
**Algorithm rationale:** 5.1=Y/PY and 5.2=5.3=N/PN -> Low

## Overall risk of bias

**Overall judgment: Low**

**Rationale:** Low in all 5 domains

## Quality flags
- NI answers: 0
- High-uncertainty signaling questions: None
- Human review priority: LOW

## Limitations of this assessment
This is an automated draft assessment. Human verification is required, especially for 0 NI answer(s) and high-uncertainty SQs: None.